Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Treasury Shares (2016 - 2025)

Ani Pharmaceuticals' Treasury Shares history spans 12 years, with the latest figure at $33.2 million for Q4 2025.

  • For Q4 2025, Treasury Shares rose 58.03% year-over-year to $33.2 million; the TTM value through Dec 2025 reached $33.2 million, up 58.03%, while the annual FY2025 figure was $33.2 million, 58.03% up from the prior year.
  • Treasury Shares for Q4 2025 was $621296.0 at Ani Pharmaceuticals, up from $613972.0 in the prior quarter.
  • Across five years, Treasury Shares topped out at $1.2 million in Q3 2022 and bottomed at $3000.0 in Q3 2021.
  • The 5-year median for Treasury Shares is $393000.0 (2024), against an average of $377518.8.
  • The largest annual shift saw Treasury Shares tumbled 50.0% in 2021 before it surged 256.82% in 2025.
  • A 5-year view of Treasury Shares shows it stood at $3.1 million in 2021, then surged by 62.49% to $5.1 million in 2022, then soared by 97.9% to $10.1 million in 2023, then skyrocketed by 108.71% to $21.0 million in 2024, then surged by 58.03% to $33.2 million in 2025.
  • Per Business Quant, the three most recent readings for ANIP's Treasury Shares are $33.2 million (Q4 2025), $32.6 million (Q3 2025), and $31.6 million (Q2 2025).